Back Hepatitis C

Hepatitis C

Grazoprevir/Elbasvir Hepatitis C Treatment Works Wells for People Who Inject Drugs

Merck's grazoprevir/elbasvir hepatitis C regimen was well-tolerated and cured more than 90% of injection drug users receiving opioid substitution therapy, according to results from the C-EDGE CO-STAR study published in the August 9 online edition of Annals of Internal Medicine. The investigators reported that adherence was good even though many study participants continued to use illicit drugs.

alt

FDA Approves Once-Daily Coformulation of AbbVie's Viekira Regimen

The U.S. Food and Drug Administration (FDA) has approved a new once-daily coformulation of AbbVie's paritaprevir-based "3D" regimen for hepatitis C virus (HCV) genotype 1, to be sold as Viekira XR, the company announced this week. AbbVie also said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on a shorter 12-week course of treatment with Viekirax for HCV genotype 4 patients with liver cirrhosis.

alt

Hepatitis C Antigen Testing Could Eliminate Need for 2-Step HCV Testing

Testing for hepatitis C virus (HCV) core antigen could eventually replace the current 2-step procedure for diagnosing chronic hepatitis C infection in lower- and middle-income countries, speeding up access to treatment and improving retention in care, a systematic review designed to inform World Health Organization hepatitis C testing guidelines has found.

alt

Advocates Launch Hepatitis Elimination Campaign on World Hepatitis Day

Coinciding with World Hepatitis Day on July 28, global advocates launched a new NOHep initiative to eliminate viral hepatitis -- including life-threatening chronic hepatitis B and C -- by the year 2030. To find out more, visit www.NOhep.org or follow the #NOhep hashtag on Twitter.

alt

Successful Hepatitis C Treatment Reduces Portal Hypertension

Direct-acting antiviral therapy that produces a sustained virological response can lead to reduction in portal vein pressure, which causes some of the most serious complications of cirrhosis, according to a report in the May 26 online edition of the Journal of Hepatology. However, the researchers cautioned, reversal of portal hypertension is less likely if liver damage is too advanced, providing an argument for earlier treatment.

alt

AASLD/IDSA Hepatitis C Guidelines Updated to Include New Therapies

The American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA this week updated their hepatitis C guidelines to add newly approved direct-acting antiviral (DAA) regimens, offering more options for people with HCV genotypes other than 1 or 4. The full guidance is available online at HCVguidelines.org.

alt

World Health Assembly Adopts Strategies for HIV, Viral Hepatitis, and STIs

The 194 member states participating in the 69th World Health Assembly, which governs the World Health Organization (WHO) in late May unanimously approved the adoption of WHO's draft global health sector strategies for management of HIV, viral hepatitis, and sexually transmitted infections (STIs) through the year 2021.

alt

FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes

On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.

alt

DDW 2016: Modern DAA Regimens Cost Less Per Cure than Older Hepatitis C Treatments

The cost of treating chronic hepatitis C with sofosbuvir/ledipasvir (Harvoni) with or without ribavirin is lower than the cost of prior interferon-based therapy with first-generation direct-acting antivirals, in part because the newer regimen is well-tolerated and requires less management of side effects, according to a Kaiser Permanente study presented at Digestive Disease Week 2016 last month in San Diego.

alt